ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis

Acotec Scientific

Status: Enrolling

Conditions: Intracranial Atherosclerosis; Stroke

Treatments: Device: drug (paclitaxel) coated balloon; Device: PTA balloon

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04627870

ACOART intracranial ISR pilot

Details and patient eligibility

About

The purpose of the study is to evaluate the safety and feasibility of drug coated balloon in treatment of intracranial in-stent restenosis.

Full description

This study is a prospective, multi-center, randomized controlled trial using drug coated balloon versus uncoated PTA balloon in treatment of intracranial in-stent restenosis.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 80 years of age
• Confirmed by DSA: in-stent restenosis (ISR) at intracranial segment of internal carotid artery, middle cerebral artery, basilar artery and vertebral artery; ISR is defined as >50% stenosis within or immediately adjacent (within 5 mm) of the implanted stent and >20% absolute luminal loss
• presence of ISR associated ischemic stroke or transient ischemic attacks even with medical treatment and strict control of risk factor
• asymptomatic ISR with severe hypoperfusion in the ISR territories, confirmed by a cerebral blood flow decrease of ≥30% when compared with the perfusion on the contralateral side for anterior circulation lesions or the anterior circulation territory for posterior circulation lesions on CT perfusion, and/or by an American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) Collateral Flow Grading System score <3 on DSA.
• the diameter of target vessel is 2.0-4.5mm
• there is only one intracranial ISR lesion per subject
• baseline mRS score ≤2
• Voluntarily participate in this study and sign the informed consent form

Exclusion criteria

• Patients with stroke within 2 weeks before procedure;
• any history of brain parenchyma or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days.
• Those who have received thrombolysis within 24 hours before procedure;
• Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline)
• patients with thrombus in target vessels.
• in addition to ISR lesions, there are other primary intracranial lesions that need endovascular treatment.
• Major surgery (including open femoral, aortic or carotid artery surgery) is planned within the past 30 days or within 90 days.
• patients with renal artery, iliac artery and cardiac coronary artery requiring simultaneous intervention.
• Combined with intracranial tumors, aneurysms or intracranial arteriovenous malformations.
• Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;
• patients with myocardial infarction within 6 weeks before procedure.
• those who cannot tolerate general anesthesia due to insufficiency of heart, lung and other important organs.
• patients with known severe hepatic and renal dysfunction.
• patients with hemoglobin < 100g / L, platelet count < 100,000 / mm3, INR > 1.5or with uncorrectable factors leading to bleeding.
• patients who cannot receive dual antiplatelet therapy due to existing diseases or who are tested to be tolerant to dual antiplatelet therapy.
• Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs
• current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 110mmHg).
• Life expectancy < 1 year.
• pregnant or lactating women.
• patients who are unable to complete follow-up due to cognitive, emotional disorders or mental illness.
• Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programme;
• According to the judgement of the investigator, other situations that are not suitable for enrollment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

20 participants in 2 patient groups

DCB group

Experimental group

Description:

use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis

Treatment:

Device: drug (paclitaxel) coated balloon

PTA group

Active Comparator group

Description:

use PTA balloon to treat intracranial in-stent restenosis

Treatment:

Device: PTA balloon